GcMAF is a is a human protein. It acts as a “director” of your immune system. But viruses and malignant cells like cancer send out an enzyme called Nagalase that prevents production of your GcMAF: that neutralises your immune system. So diseases become chronic, and cancer cells grow unchecked.
This study concluded that, in addition to its ability to activate tumor killing immune cells, GcMAF has direct anti tumor-forming effects on endothelial cells independent of tissue origin.
This study: Sixteen nonanemic prostate cancer patients received weekly administration of 100 ng of GcMAF. As the MAF precursor activity increased, their serum Nagalase activity decreased…After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had very low serum Nagalase levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years.
This study: Patients with advanced cancer were treated at the Immuno Biotech Treatment Centre with OA-GcMAF-based integrative immunotherapy in combination with a low-carbohydrate, high-protein diet, fermented milk products containing naturally-produced GcMAF, Vitamin D3, omega-3 fatty acids and low-dose acetylsalicylic acid.
Measuring the tumour by ultrasonographic techniques, we observed a decrease of tumour volume of about 25%.
These observations demonstrate that OA [oleic Acid], GcMAF and NO [Nitric Oxide] can be properly combined and specifically delivered to advanced cancer patients with significant effects on immune system stimulation and tumour volume reduction avoiding harmful side-effects.
This study: Here, we report the results of the administration of GcMAF to a heterogeneous cohort of patients with histologically diverse, advanced neoplasms, generally considered as “incurable” diseases. In most cases, GcMAF therapy was initiated at late stages of tumor progression…the response to GcMAF was generally robust and some trends emerged. All patients (20) presented with elevated serum nagalase activity, well above normal values. All patients but one showed a significant decrease of serum nagalase activity upon weekly GcMAF injections. Decreased nagalase activity was associated with improved clinical conditions and no adverse side effects were reported.
The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture. In addition to these considerations, it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children. Study